-
Opthea Opens Patient Enrollment in the Asia-Pacific Region for the OPT-302 ShORe and COAST Phase 3 Trials in Wet AMD
19 Oct 2021 10:50 GMT
… with either 0.5 mg ranibizumab (Lucentis®), or 2.0 … S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) … unmet need in the treatment of highly prevalent and … pharmaceutical products to a marketable stage. The lengthy clinical trial …
-
The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs
18 Oct 2021 12:16 GMT
… vaccines.
Avadel Pharmaceuticals plc (NASDAQ: AVDL) faced a setback after the FDA … drug.
Here are the key catalysts that could impact trading in biotech … System with ranibizumab for neovascular … NanoViricides COVID-19 Treatment Candidate Found Effective …
-
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
01 Oct 2021 20:38 GMT
… anti-VEGF treatment burden
Phase II trial expanded to … receiving monthly injections of ranibizumab also demonstrated stable CRT, … a leading clinical-stage biotechnology company seeking to improve … future operations and clinical trials. REGENXBIO has based …
-
FDA Approves Biosimilar Drug for Treating Macular Degeneration
21 Sep 2021 05:52 GMT
… "Obamacare"). The drug is Byooviz (ranibizumab-nuna), a biosimilar to … conditions. Specifically, according to the FDA announcement, Byooviz is approved for … to provide greater access to treatment options for patients, increase competition …
-
FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions
20 Sep 2021 15:36 GMT
… biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases … increased intraocular fluid pressure.
The FDA granted approval of Byooviz to … veterinary drugs, vaccines and other biological products for human use, and medical devices …
-
FDA Approves Samsung Bioepis' Byooviz, A Proposed Biosimilar To Lucentis - Quick Facts
20 Sep 2021 12:32 GMT
… Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), … a biosimilar referencing Lucentis (ranibizumab) for the treatment … choroidal neovascularization (mCNV).
Ranibizumab is an anti-vascular …
-
Ranibizumab Biosimilars Insight and Ranibizumab MOA by DelveInsight
10 Sep 2021 17:13 GMT
… helps to understand clinical trial details, expressive pharmacological action … releases. Ranibizumab Biosimilars Insights: Marketed Drugs
Razumab: Intas Pharmaceuticals
Razumab is … ongoing Phase III trial of its Xlucane (ranibizumab) biosimilar product, …
-
Samsung Bioepis gets nod for sale of ophthalmology biosimilar drug in Europe
23 Aug 2021 08:37 GMT
… ranibizumab biosimilar, previously known as SB11, which references Swiss pharmaceutical … 2020.
Lucentis is a medication for ophthalmic disease and … in phase three clinical trial evaluation.
Samsung Bioepis, … and pipelines of blockbuster drugs in its portfolio. …
-
AbbVie Returns Eye Drug Candidate To Molecular Partners
09 Aug 2021 11:21 GMT
… than 50% fewer injections versus ranibizumab (13 vs. 6) dosed … 2020, AbbVie received an FDA Complete Response Letter for abicipar … benefit-risk ratio in the treatment of neovascular (wet) age … filings with the European Medicines Agency and the Japanese …
-
Polpharma Biologics Group Announces That Its Joint Venture Bioeq Has Submitted a Biologics License Application (BLA) for Biosimilar Ranibizumab to the U.S. Food and Drug Administration (FDA)
06 Aug 2021 11:32 GMT
… Drug Administration (FDA) for their biosimilar candidate of the ophthalmological drug Ranibizumab … promise of treatment choice and … number of medical conditions across … SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL OPTICAL HEALTH FDA CLINICAL TRIALS
SOURCE …
About
© 1995-2021